In the wake of late-October reports of adverse events with Cordis’ (Miami Lakes, Florida) Cypher drug-eluting stent, the Johnson & Johnson (New Brunswick, New Jersey) unit sponsored a webcast in early December that included prominent interventional cardiologists as well as a top executive from the company.